🇺🇸 FDA
Pipeline program

DURVALUMAB, PACLITAXEL ALBUMIN-BOUND, Ceralasertib

IFOM-CPT008/2022/PO0

Phase 2 small_molecule active

Quick answer

DURVALUMAB, PACLITAXEL ALBUMIN-BOUND, Ceralasertib for ADVANCED TRIPLE NEGATIVE BREAST CANCER is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

Program details

Company
Fondazione Telethon ETS
Indication
ADVANCED TRIPLE NEGATIVE BREAST CANCER
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials